The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Multiple sclerosis (MS) is the most prevalent demyelinating disease of the central nervous system (CNS). It affects over 400,000 people in the USA alone and is a common disease world wide. This book will cover a new and emerging field in the development of strategies to treat MS. Until now, the only therapies available for MS treatment have been those directed against inflammation and the immune attack on the CNS. Other treatments are used for symptomatic relief. Remyelination of the CNS has been purely an experimental procedure to date, with many years of research on experimental remyelination in animal models of MS and other myelin disease. As more becomes known about the underlying pathophysiology of MS, it has become apparent that axon loss is a critical component of this primary demyelinating disease and that remyelination of axons at risk, i.e. demyelinated axons, may be the best neuroprotection available. Thus the idea of repairing myelin to both restore conduction to demyelinated fibers, as well as protecting them against future loss, is being seriously explored as a translational therapy. The purpose of this book will be to bring together the experts in the field to discuss what is required to move forward into the clinical application of tissue repair and neuroprotection. The book will begin with a discussion on myelin and the myelinating cell of the CNS and the current state-of-the- art on the cell and molecular biology of the cell, with particular reference toward myelin repair. The book will conclude with a chapter(s) on the clinical application of new myelin repair and axonal protection therapies and the methods by which these new therapies will be evaluated in clinical trials.